Congressional Republicans may need to “scramble” to help ensure meaningful Medicare coverage for Eisai Co., Ltd./Biogen, Inc.’s lecanemab if it is approved by the US Food and Drug Administration for Alzheimer's disease next year, according to health policy expert Jennifer Young.
Young who is a partner at the health care policy consultancy Tarplin, Downs and Young, discussed House Republican’s health care priorities in the coming session as they take control of...